Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment

Autores
Fernandez, Ivana; Tonietti, Miriam; Camberos, Maria del Carmen; Bergada, Ignacio; Schenone, Andrea; Szlago, Marina; Tellechea, Mariana Lorena; Fretchtel, Gustavo; Trifone, Liliana; Cresto, Juan Carlos
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
n the first part, this article review the accepted knowledge of type 1 diabetes, its physiopathology, the importance of cytokines and the induction of apoptosis and necrosis during its evolution. Throughout this work we describe in more detail the inhibition of this mechanism of cell destruction by acetyl-L-carnitine and nicotinamide. We also explain the complementary action of their association which gave support to the treatment. In the second part, we present the complete evolution of 8 children treated with the oral medication of 50 mg/Kg of acetyl-L-carnitine plus 25 mg/Kg of nicotinamide during 5 years. We published the first 2 years of evolution under treatment in these children (JPEM 26: 347, 2013). The children had positive auto-antibodies and were consanguineous of type 1 diabetic patients. The intravenous glucose tolerance test (IVGTT) showed a first phase of insulin release minor of 48 μU to enter in the protocol, and the same test was used for children evolution. Seven out eight children stopped the treatment because they normalized the metabolic parameters and no one became diabetic. All children increased the insulin response to IVGTT (between 1.44 to 5.69 times). Along the treatment, seven of these eight children turned their positive auto-antibodies into negatives.
Fil: Fernandez, Ivana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; Argentina
Fil: Tonietti, Miriam. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; Argentina
Fil: Camberos, Maria del Carmen. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; Argentina
Fil: Bergada, Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; Argentina
Fil: Schenone, Andrea. Fundación de las Enfermedades Neurometabólicas; Argentina
Fil: Szlago, Marina. Fundación de las Enfermedades Neurometabólicas; Argentina
Fil: Tellechea, Mariana Lorena. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Fretchtel, Gustavo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Trifone, Liliana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; Argentina
Fil: Cresto, Juan Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; Argentina
Materia
Acetyl-L-Carnitine and Nicotinamide treatment
Prevention of type 1 Diabetes
Evaluation of treatment
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/8185
Acceder
id CONICETDig_18d3e84685a97e848a1fb1db6b13a117
oai_identifier_str oai:ri.conicet.gov.ar:11336/8185
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years TreatmentFernandez, IvanaTonietti, MiriamCamberos, Maria del CarmenBergada, IgnacioSchenone, AndreaSzlago, MarinaTellechea, Mariana LorenaFretchtel, GustavoTrifone, LilianaCresto, Juan CarlosAcetyl-L-Carnitine and Nicotinamide treatmentPrevention of type 1 DiabetesEvaluation of treatmenthttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3n the first part, this article review the accepted knowledge of type 1 diabetes, its physiopathology, the importance of cytokines and the induction of apoptosis and necrosis during its evolution. Throughout this work we describe in more detail the inhibition of this mechanism of cell destruction by acetyl-L-carnitine and nicotinamide. We also explain the complementary action of their association which gave support to the treatment. In the second part, we present the complete evolution of 8 children treated with the oral medication of 50 mg/Kg of acetyl-L-carnitine plus 25 mg/Kg of nicotinamide during 5 years. We published the first 2 years of evolution under treatment in these children (JPEM 26: 347, 2013). The children had positive auto-antibodies and were consanguineous of type 1 diabetic patients. The intravenous glucose tolerance test (IVGTT) showed a first phase of insulin release minor of 48 μU to enter in the protocol, and the same test was used for children evolution. Seven out eight children stopped the treatment because they normalized the metabolic parameters and no one became diabetic. All children increased the insulin response to IVGTT (between 1.44 to 5.69 times). Along the treatment, seven of these eight children turned their positive auto-antibodies into negatives.Fil: Fernandez, Ivana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; ArgentinaFil: Tonietti, Miriam. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; ArgentinaFil: Camberos, Maria del Carmen. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; ArgentinaFil: Bergada, Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; ArgentinaFil: Schenone, Andrea. Fundación de las Enfermedades Neurometabólicas; ArgentinaFil: Szlago, Marina. Fundación de las Enfermedades Neurometabólicas; ArgentinaFil: Tellechea, Mariana Lorena. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Fretchtel, Gustavo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Trifone, Liliana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; ArgentinaFil: Cresto, Juan Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; ArgentinaOmics International2015-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/8185Fernandez, Ivana; Tonietti, Miriam; Camberos, Maria del Carmen; Bergada, Ignacio; Schenone, Andrea; et al.; Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment; Omics International; Immunome Research; 11; 2; 6-2015; 1000094-10000941745-7580enginfo:eu-repo/semantics/altIdentifier/url/http://www.omicsonline.com/open-access/acetyllcarnitine-and-nicotinamide-for-prevention-of-type-1-diabetes-iliterature-review-which-gave-support-to-the-treatment-iicase-report-evaluation-of-five-years-treatment-1745-7580-1000094.php?aid=55708info:eu-repo/semantics/altIdentifier/doi/10.4172/17457580.1000094info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:01:28Zoai:ri.conicet.gov.ar:11336/8185instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:01:28.999CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
title Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
spellingShingle Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
Fernandez, Ivana
Acetyl-L-Carnitine and Nicotinamide treatment
Prevention of type 1 Diabetes
Evaluation of treatment
title_short Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
title_full Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
title_fullStr Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
title_full_unstemmed Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
title_sort Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment
dc.creator.none.fl_str_mv Fernandez, Ivana
Tonietti, Miriam
Camberos, Maria del Carmen
Bergada, Ignacio
Schenone, Andrea
Szlago, Marina
Tellechea, Mariana Lorena
Fretchtel, Gustavo
Trifone, Liliana
Cresto, Juan Carlos
author Fernandez, Ivana
author_facet Fernandez, Ivana
Tonietti, Miriam
Camberos, Maria del Carmen
Bergada, Ignacio
Schenone, Andrea
Szlago, Marina
Tellechea, Mariana Lorena
Fretchtel, Gustavo
Trifone, Liliana
Cresto, Juan Carlos
author_role author
author2 Tonietti, Miriam
Camberos, Maria del Carmen
Bergada, Ignacio
Schenone, Andrea
Szlago, Marina
Tellechea, Mariana Lorena
Fretchtel, Gustavo
Trifone, Liliana
Cresto, Juan Carlos
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Acetyl-L-Carnitine and Nicotinamide treatment
Prevention of type 1 Diabetes
Evaluation of treatment
topic Acetyl-L-Carnitine and Nicotinamide treatment
Prevention of type 1 Diabetes
Evaluation of treatment
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv n the first part, this article review the accepted knowledge of type 1 diabetes, its physiopathology, the importance of cytokines and the induction of apoptosis and necrosis during its evolution. Throughout this work we describe in more detail the inhibition of this mechanism of cell destruction by acetyl-L-carnitine and nicotinamide. We also explain the complementary action of their association which gave support to the treatment. In the second part, we present the complete evolution of 8 children treated with the oral medication of 50 mg/Kg of acetyl-L-carnitine plus 25 mg/Kg of nicotinamide during 5 years. We published the first 2 years of evolution under treatment in these children (JPEM 26: 347, 2013). The children had positive auto-antibodies and were consanguineous of type 1 diabetic patients. The intravenous glucose tolerance test (IVGTT) showed a first phase of insulin release minor of 48 μU to enter in the protocol, and the same test was used for children evolution. Seven out eight children stopped the treatment because they normalized the metabolic parameters and no one became diabetic. All children increased the insulin response to IVGTT (between 1.44 to 5.69 times). Along the treatment, seven of these eight children turned their positive auto-antibodies into negatives.
Fil: Fernandez, Ivana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; Argentina
Fil: Tonietti, Miriam. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; Argentina
Fil: Camberos, Maria del Carmen. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; Argentina
Fil: Bergada, Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; Argentina
Fil: Schenone, Andrea. Fundación de las Enfermedades Neurometabólicas; Argentina
Fil: Szlago, Marina. Fundación de las Enfermedades Neurometabólicas; Argentina
Fil: Tellechea, Mariana Lorena. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Fretchtel, Gustavo. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
Fil: Trifone, Liliana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutierrez"; Argentina
Fil: Cresto, Juan Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones Endocrinológicas; Argentina
description n the first part, this article review the accepted knowledge of type 1 diabetes, its physiopathology, the importance of cytokines and the induction of apoptosis and necrosis during its evolution. Throughout this work we describe in more detail the inhibition of this mechanism of cell destruction by acetyl-L-carnitine and nicotinamide. We also explain the complementary action of their association which gave support to the treatment. In the second part, we present the complete evolution of 8 children treated with the oral medication of 50 mg/Kg of acetyl-L-carnitine plus 25 mg/Kg of nicotinamide during 5 years. We published the first 2 years of evolution under treatment in these children (JPEM 26: 347, 2013). The children had positive auto-antibodies and were consanguineous of type 1 diabetic patients. The intravenous glucose tolerance test (IVGTT) showed a first phase of insulin release minor of 48 μU to enter in the protocol, and the same test was used for children evolution. Seven out eight children stopped the treatment because they normalized the metabolic parameters and no one became diabetic. All children increased the insulin response to IVGTT (between 1.44 to 5.69 times). Along the treatment, seven of these eight children turned their positive auto-antibodies into negatives.
publishDate 2015
dc.date.none.fl_str_mv 2015-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/8185
Fernandez, Ivana; Tonietti, Miriam; Camberos, Maria del Carmen; Bergada, Ignacio; Schenone, Andrea; et al.; Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment; Omics International; Immunome Research; 11; 2; 6-2015; 1000094-1000094
1745-7580
url http://hdl.handle.net/11336/8185
identifier_str_mv Fernandez, Ivana; Tonietti, Miriam; Camberos, Maria del Carmen; Bergada, Ignacio; Schenone, Andrea; et al.; Acetyl-L-Carnitine and Nicotinamide for Prevention of Type 1Diabetes I-Literature Rewiew Which Gave Support to the Treatment. II-Case Report, Evaluation of Five Years Treatment; Omics International; Immunome Research; 11; 2; 6-2015; 1000094-1000094
1745-7580
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.omicsonline.com/open-access/acetyllcarnitine-and-nicotinamide-for-prevention-of-type-1-diabetes-iliterature-review-which-gave-support-to-the-treatment-iicase-report-evaluation-of-five-years-treatment-1745-7580-1000094.php?aid=55708
info:eu-repo/semantics/altIdentifier/doi/10.4172/17457580.1000094
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Omics International
publisher.none.fl_str_mv Omics International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613809022435328
score 13.070432

Publicaciones similares